Eidos Therapeutics (Eidos Therapeutics) Days Payable : 0.00 (As of Sep. 2020)

View and export this data going back to 2018. Start your Free Trial

What is Eidos Therapeutics Days Payable?

Eidos Therapeutics's average Accounts Payable for the three months ended in Sep. 2020 was $2.31 Mil. Eidos Therapeutics's Cost of Goods Sold for the three months ended in Sep. 2020 was $0.00 Mil.

The historical rank and industry rank for Eidos Therapeutics's Days Payable or its related term are showing as below:

During the past 4 years, Eidos Therapeutics's highest Days Payable was 369.48. The lowest was 0.00. And the median was 369.48.

EIDX's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 148.78
* Ranked among companies with meaningful Days Payable only.

Eidos Therapeutics's Days Payable declined from Sep. 2019 (98.71) to Sep. 2020 (0.00). It may suggest that Eidos Therapeutics accelerated paying its suppliers.

Eidos Therapeutics Days Payable Historical Data

The historical data trend for Eidos Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eidos Therapeutics Days Payable Chart

Eidos Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Days Payable

372.81

Eidos Therapeutics Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20
Days Payable	Get a 7-Day Free Trial											98.71	-	-	-	-

Competitive Comparison of Eidos Therapeutics's Days Payable

For the Biotechnology subindustry, Eidos Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eidos Therapeutics's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eidos Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Eidos Therapeutics's Days Payable falls into.

Eidos Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Eidos Therapeutics's Days Payable for the fiscal year that ended in Dec. 2019 is calculated as

	Days Payable (A: Dec. 2019 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2018 )	+	Accounts Payable (A: Dec. 2019 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2019 )	*	Days in Period
=	( (1.956	+	3.151)	/	2 )	/	2.5	*	365
=	2.5535					/	2.5	*	365
=	372.81

Eidos Therapeutics's Days Payable for the quarter that ended in Sep. 2020 is calculated as:

	Days Payable (Q: Sep. 2020 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2020 )	+	Accounts Payable (Q: Sep. 2020 ))	/	count )	/	Cost of Goods Sold (Q: Sep. 2020 )	*	Days in Period
=	( (2.24	+	2.381)	/	2 )	/	0	*	365 / 4
=	2.3105					/	0	*	365 / 4
=	N/A

Eidos Therapeutics Days Payable Related Terms

Thank you for viewing the detailed overview of Eidos Therapeutics's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Eidos Therapeutics (Eidos Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eidos Therapeutics Inc (NAS:EIDX) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

101 Montgomery Street, Suite 2000, San Francisco, CA, USA, 94104

Website

https://www.eidostx.com

Eidos Therapeutics Inc is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. TTR is a protein that occurs naturally in the form of a tetramer and performs multiple beneficial roles, including the transport of essential hormones and vitamins. The company's product candidate, AG10, is an orally-administered small molecule designed to potently stabilize tetrameric TTR.

Executives

Uma Sinha	director, officer: Chief Scientific Officer	C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94101
Franco Valle	officer: Senior Vice President, Finance	999 SKYWAY ROAD, SUITE 150, SAN CARLOS CA 94070
Cameron Turtle	officer: Chief Business Officer	C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94104
Jonathan C Fox	officer: See Remarks	C/O MYOKARDIA, INC., 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
Suzanne Sawochka Hooper	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Douglas Rohlen	director	3600 HOLLY LANE NORTH, SUITE 40 PLYMOUTH MN 55447
Eric Aguiar	director	888 7TH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Rajeev M. Shah	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ali J. Satvat	director, 10 percent owner	C/O KOHLBERG KRAVIS ROBERTS & CO., 2800 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
William Lis	director	PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Christine Siu	officer: CFO and Secretary	C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94101
Bridgebio Pharma, Inc.	10 percent owner	421 KIPLING STREET PALO ALTO CA 94301
Neil Kumar	director, 10 percent owner, officer: Chief Executive Officer	C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR, STE 250, PALO ALTO CA 94304
Hoyoung Huh	director	C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Peter Kolchinsky	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116